Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

Virologic Response and Safety of the Abacavir/Lamivudine Fixed-Dose Formulation as Part of Highly Active Antiretroviral Therapy: Analyses of Six Clinical Studies

(2009) Belinda Ha et al.   HIV CLINICAL TRIALS

Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

(2009) Paul E. Sax et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel

(2008) Martin S. Hirsch et al.   CLINICAL INFECTIOUS DISEASES

High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients

(2008) Michael Saag et al.   CLINICAL INFECTIOUS DISEASES

Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study

(2008) Richard Elion et al.   HIV CLINICAL TRIALS

Antiretroviral Treatment of Adult HIV Infection

(2008) Scott M. Hammer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

(2008) Jean-Michel Molina et al.   LANCET

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE